Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lawrence Zisman
Pulmokine, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Pulmokine Inc.
Other : The potentially conflicted investigator is an employee of Pulmokine Inc. and majority shareholder in Pulmokine Inc.; Pulmokine Inc. is not public and is not traded.
The potentially conflicted investigator is an employee of Pulmokine Inc. and a majority shareholder in Pulmokine Inc. Pulmokine Inc. is not public and its shares are not traded. According to 42 CFR 50.603 "the term significant financial interest does not include the following types of financial interests: salary, royalties, or other remuneration paid by the Institution to the Investigator if the Investigator is currently employed or otherwise appointed by the Institution, including intellectual property rights assigned to the Institution and agreements to share in royalties related to such rights; any ownership interest in the Institution held by the Investigator, if the Institution is a commercial or for‐profit organization." Nevertheless, the Institution recognizes that Institution is relying on the funded research to move its drug candidate towards clinical trials and eventual commercialization. Therefore, even though strictly speaking criteria for a significant financial interest are not met, the institution has implemented a management plan.
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension
Zisman, Lawrence Pulmonary arterial hypertension is a devastating disease with a high morbidity and mortality. This project is relevant to public health because it will ultimately lead to a new treatment for pulmonary arterial hypertension. Public Health Relevance Statement Page 8
Filed on August 10, 2015.
Tell us what you know about Lawrence Zisman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.